<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710669</url>
  </required_header>
  <id_info>
    <org_study_id>151952</org_study_id>
    <secondary_id>1R01HL124935-01A1</secondary_id>
    <nct_id>NCT02710669</nct_id>
  </id_info>
  <brief_title>New Formulations of Propafenone to Treat Atrial Fibrillation</brief_title>
  <official_title>Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two
      compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will
      randomize participants to (R)-propafenone, (S)-propafenone, or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is a common cardiac arrhythmia that needs development of more effective
      medications. Propafenone is a medicine currently used to treat atrial fibrillation and is a
      mixture of two compounds, (R)-propafenone and (S)-propafenone. The investigators have
      discovered that purified (R)-propafenone may be more effective than (S)-propafenone for
      treatment of atrial fibrillation, and that (S)-propafenone reduces the efficacy of
      (R)-propafenone when administered as a mixture. This study will compare the ability of
      (R)-propafenone, (S)-propafenone, and placebo to suppress the induction of atrial
      fibrillation in participants undergoing an atrial fibrillation ablation procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction of atrial fibrillation (yes or no)</measure>
    <time_frame>intraoperative</time_frame>
    <description>A rapid atrial pacing protocol will be used to attempt to induce atrial fibrillation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">243</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>(R)-propafenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(S)-Propafenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) is infused over 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R)-propafenone</intervention_name>
    <arm_group_label>(R)-propafenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(S)-Propafenone</intervention_name>
    <arm_group_label>(S)-Propafenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. History of atrial fibrillation

          2. Greater than or equal to 18 years of age

          3. Scheduled to undergo an atrial fibrillation ablation procedure

          4. Able to provide written informed consent

        Exclusion:

          1. Long-standing persistent atrial fibrillation at the time of ablation (greater than 1
             year of a continuous atrial fibrillation episode)

          2. Is in atrial fibrillation or atrial flutter the morning of the ablation procedure

          3. The presence of any of the following in a patient without a permanent pacemaker for
             implantable cardiac defibrillator

               1. sick sinus syndrome indicated by the inability to previously tolerate an
                  antiarrhythmic drug due to bradycardia

               2. sinus bradycardia with a heart rate less than 50 beats per minute at the time of
                  study drug administration

               3. right bundle branch block, left bundle branch block, or bifascicular block

               4. PR-interval &gt; 280ms, or history of 2nd or 3rd degree atrioventricular block

          4. Concomitant use of CYP3A4 and CYP2D6 inhibitors

          5. Previous surgical or catheter ablation for atrial fibrillation or Cox-Maze procedure

          6. Amiodarone use within 3 months prior to enrollment

          7. Antiarrhythmic drug (other than amiodarone) within 5 half-lives prior to atrial
             fibrillation ablation

          8. Expected life span &lt; 1 year

          9. Creatinine clearance &lt;30 mL/min

         10. Reversible cause of atrial fibrillation (ie. thyrotoxicosis)

         11. Unrevascularized coronary artery disease

         12. Canadian class IV angina

         13. Left ventricular ejection fraction &lt;40%

         14. New York Heart Association Class III or IV symptoms

         15. Previous heart transplantation

         16. Planned heart transplantation or ventricular assist device

         17. Cardiac/thoracic surgery &lt;6 months prior to enrollment

         18. Severe asthma or chronic obstructive pulmonary disease

         19. Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Knollmann, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ben Shoemaker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane M Crawford, RN</last_name>
    <phone>615-322-3304</phone>
    <email>diane.m.crawford@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben Shoemaker, MD</last_name>
    <phone>615-875-9730</phone>
    <email>moore.b.shoemaker@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Faggioni M, Savio-Galimberti E, Venkataraman R, Hwang HS, Kannankeril PJ, Darbar D, Knollmann BC. Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. Circ Arrhythm Electrophysiol. 2014 Apr;7(2):313-20. doi: 10.1161/CIRCEP.113.000994. Epub 2014 Feb 3.</citation>
    <PMID>24493699</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Bjorn Knollmann</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

